Taysha Gene Therapies, Inc. Increase (Decrease) in Contract with Customer, Liability
Taysha Gene Therapies, Inc. (TSHA) reported Increase (Decrease) in Contract with Customer, Liability of -$9.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-11
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$5.49M.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $0.00.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$1.99M.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was -$2.30M.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$9.77M.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$8.33M.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$15.45M, a 146.04% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $33.56M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$5.49M derived: sum of 2 quarters · filed 2026-03-19 | -$7.47M derived: sum of 3 quarters · filed 2026-08-11 | -$9.77M 10-K · filed 2026-03-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.99M derived: sum of 2 quarters · filed 2026-08-11 | -$4.29M 10-Q · filed 2025-11-04 | -$6.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.29M 10-Q · filed 2026-08-11 | -$6.31M derived: sum of 3 quarters · filed 2026-08-11 | -$8.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$2.30M 10-Q · filed 2026-05-06 | -$4.32M derived: sum of 2 quarters · filed 2026-05-06 | -$6.11M derived: sum of 3 quarters · filed 2026-05-06 | -$7.22M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$3.81M derived: sum of 2 quarters · filed 2026-03-19 | -$4.92M derived: sum of 3 quarters · filed 2026-03-19 | -$8.33M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.90M derived: sum of 2 quarters · filed 2025-11-04 | -$6.31M 10-Q · filed 2025-11-04 | -$9.91M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$4.52M 10-Q · filed 2025-08-12 | -$8.13M derived: sum of 3 quarters · filed 2025-08-12 | -$12.87M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$3.41M 10-Q · filed 2025-05-15 | -$7.01M derived: sum of 2 quarters · filed 2025-05-15 | -$11.76M derived: sum of 3 quarters · filed 2025-05-15 | -$14.16M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$8.35M derived: sum of 2 quarters · filed 2025-02-26 | -$10.74M derived: sum of 3 quarters · filed 2025-02-26 | -$15.45M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$4.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$7.14M derived: sum of 2 quarters · filed 2024-11-13 | -$11.85M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$7.10M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$4.71M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $33.56M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |